Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Level39 Space39 London E14 5AB

  1. Events
  2. Venues
  3. Level39 Space39 London E14 5AB
Events at this venue
Today

Fin|Tech|Bio at Canary Wharf

Bringing together innovators, investors, and industry leaders at the intersection of finance, technology, and biotech, this event series is designed to foster insightful discussions, build [...]

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2024 | Hlx Life Sciences

Site by theLEAP

Go to Top